Lessons from the Valcyte patent battle

October 01, 2010

Archana Shanker and Nupur Maithani of Anand and Anand consider what the battle over the Valcyte patent reveals about the Indian judiciary’s approach to pharmaceutical patents

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

The Supreme Court, which is hearing two IP cases this week, should limit the power of US courts to rule on foreign sales

Rani Mehta, March 20, 2023

Safety standards wouldn’t lose copyright protection when named in law, so long as they were accessible for free online

Rani Mehta, March 17, 2023

In-house tech sources say Amgen v Sanofi has the potential to stifle their prosecution and litigation strategies if SCOTUS’s decision is too broad

Rani Mehta, March 17, 2023

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP

Max Walters, March 17, 2023

The Federal Circuit said tech firms can challenge the way the USPTO implemented Fintiv, but that won’t mean much for practitioners, say counsel

Rani Mehta, March 16, 2023

The England and Wales High Court handed down one of the most hotly anticipated FRAND rulings for some time

Max Walters, March 16, 2023

Funders discuss different IP portfolio funding options and how they decide whether to offer preferential terms and pricing

Sukanya Sarkar, March 16, 2023

The issue of the Unified Patent Court’s third central division needs resolving before IP owners can fully embrace Europe’s new era

Max Walters, March 16, 2023

Foreign firms and lawyers, including IP practitioners, can now practise in India after years of talk and no action

Sukanya Sarkar, March 15, 2023

Most Indian counsel won’t immediately look beyond the Delhi High Court for IP cases, but new forums could potentially change their minds

Sukanya Sarkar, March 15, 2023